Live Oak Private Wealth LLC increased its position in Danaher Co. (NYSE:DHR – Free Report) by 5.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,789 shares of the conglomerate’s stock after purchasing an additional 2,151 shares during the period. Danaher makes up 1.7% of Live Oak Private Wealth LLC’s investment portfolio, making the stock its 15th largest holding. Live Oak Private Wealth LLC’s holdings in Danaher were worth $10,052,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Danaher by 3.7% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 81,180 shares of the conglomerate’s stock valued at $18,635,000 after purchasing an additional 2,890 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in Danaher during the 4th quarter valued at $31,000. Telos Capital Management Inc. boosted its holdings in Danaher by 0.5% during the 4th quarter. Telos Capital Management Inc. now owns 45,031 shares of the conglomerate’s stock worth $10,337,000 after acquiring an additional 220 shares during the last quarter. McHugh Group LLC bought a new stake in shares of Danaher in the 4th quarter worth $264,000. Finally, YANKCOM Partnership purchased a new stake in shares of Danaher in the fourth quarter valued at about $237,000. Institutional investors own 79.05% of the company’s stock.
Insider Transactions at Danaher
In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.90% of the company’s stock.
Analysts Set New Price Targets
Danaher Trading Down 1.0 %
Shares of Danaher stock opened at $209.95 on Friday. The company’s 50-day moving average price is $233.96 and its 200-day moving average price is $252.39. The company has a market cap of $151.64 billion, a price-to-earnings ratio of 39.76, a PEG ratio of 2.80 and a beta of 0.83. Danaher Co. has a 12-month low of $209.10 and a 12-month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the company posted $2.09 earnings per share. On average, equities analysts expect that Danaher Co. will post 7.77 earnings per share for the current fiscal year.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.51%. Danaher’s dividend payout ratio is presently 20.45%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- What Are the FAANG Stocks and Are They Good Investments?
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- How to Invest in Insurance Companies: A Guide
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- These are the 3 Stocks Most Likely to Split in 2025
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.